[Non-coding Natural Antisense RNA: Mechanisms of Action in the Regulation of Target Gene Expression and Its Clinical Implications]
- PMID: 32378673
- DOI: 10.1248/yakushi.20-00002
[Non-coding Natural Antisense RNA: Mechanisms of Action in the Regulation of Target Gene Expression and Its Clinical Implications]
Abstract
Recent advances in high-throughput technologies have revealed that 75% of the human genome is transcribed to RNA, whereas only 3% of transcripts are translated into proteins. Consequently, many long non-coding RNAs (lncRNAs) have been identified, which has improved our understanding of the complexity of biological processes. LncRNAs comprise multiple classes of RNA transcripts that regulate the transcription, stability and translation of protein-coding genes in a genome. Natural antisense transcripts (NATs) form one such class, and the GENCODE v30 catalog contains 16193 lncRNA loci, of which 5611 are antisense loci. This review outlines our emerging understanding of lncRNAs, with a particular focus on how lncRNAs regulate gene expression using interferon-α1 (IFN-α1) mRNA and its antisense partner IFN-α1 antisense (as)RNA as an example. We have identified and characterized the asRNA that determines post-transcriptional IFN-α1 mRNA levels. IFN-α1 asRNA stabilizes IFN-α1 mRNA by cytoplasmic sense-antisense duplex formation, which may enhance the accessibility of an RNA stabilizer protein or decrease the affinity of an RNA decay factor for the RNA. IFN-α1 asRNA can also act as competing molecules in the competing endogenous (ce)RNA network with other members of the IFNA multigene family mRNAs/asRNAs, and other cellular mRNA transcripts. Furthermore, antisense oligoribonucleotides representing functional domains of IFN-α1 asRNA inhibit influenza virus proliferation in the respiratory tract of virus-infected animals. Thus, these findings support, at least in part, the rationale that dissecting the activity of NAT on gene expression regulation promises to reveal previously unanticipated biology, with potential to provide new therapeutic approaches to diseases.
Keywords: interferon-α1 antisense RNA; long non-coding RNA; mRNA stabilization; natural antisense transcript; proof-of-concept; regulatory RNA.
Similar articles
-
Stabilization of human interferon-α1 mRNA by its antisense RNA.Cell Mol Life Sci. 2013 Apr;70(8):1451-67. doi: 10.1007/s00018-012-1216-x. Epub 2012 Dec 8. Cell Mol Life Sci. 2013. PMID: 23224365 Free PMC article.
-
IFN-Alpha1 antisense RNA represses human influenza A virus growth in a guinea pig system.Front Biosci (Landmark Ed). 2019 Mar 1;24(4):798-818. doi: 10.2741/4752. Front Biosci (Landmark Ed). 2019. PMID: 30844714
-
Interferon-alpha competing endogenous RNA network antagonizes microRNA-1270.Cell Mol Life Sci. 2015 Jul;72(14):2749-61. doi: 10.1007/s00018-015-1875-5. Epub 2015 Mar 7. Cell Mol Life Sci. 2015. PMID: 25746225 Free PMC article.
-
Natural antisense and noncoding RNA transcripts as potential drug targets.Drug Discov Today. 2006 Jun;11(11-12):503-8. doi: 10.1016/j.drudis.2006.04.013. Drug Discov Today. 2006. PMID: 16713901 Review.
-
Long antisense non-coding RNAs and the epigenetic regulation of gene expression.Biomol Concepts. 2013 Aug;4(4):411-5. doi: 10.1515/bmc-2013-0014. Biomol Concepts. 2013. PMID: 25436590 Review.
Cited by
-
The role of ncRNA regulatory mechanisms in diseases-case on gestational diabetes.Brief Bioinform. 2023 Nov 22;25(1):bbad489. doi: 10.1093/bib/bbad489. Brief Bioinform. 2023. PMID: 38189542 Free PMC article. Review.
-
Deciphering the Epigenetic Symphony of Cancer: Insights and Epigenetic Therapies Implications.Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241250317. doi: 10.1177/15330338241250317. Technol Cancer Res Treat. 2024. PMID: 38780251 Free PMC article. Review.
-
Role of non-coding RNAs and exosomal non-coding RNAs in retinoblastoma progression.Front Cell Dev Biol. 2022 Dec 23;10:1065837. doi: 10.3389/fcell.2022.1065837. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 36619866 Free PMC article. Review.
-
NcRNA: key and potential in hearing loss.Front Neurosci. 2024 Jan 17;17:1333131. doi: 10.3389/fnins.2023.1333131. eCollection 2023. Front Neurosci. 2024. PMID: 38298898 Free PMC article. Review.
-
Epigenetic modifications: Key players in cancer heterogeneity and drug resistance.Transl Oncol. 2024 Jan;39:101821. doi: 10.1016/j.tranon.2023.101821. Epub 2023 Nov 4. Transl Oncol. 2024. PMID: 37931371 Free PMC article.